Source comparison
Thymosin Alpha-1 vs Other Autoimmune Peptides: Treatment Comparison
Before choosing a peptide protocol, understanding how thymosin alpha-1 compares to other immune-modulating compounds clarifies which mechanism matches your specific autoimmune profile. Thymosin Alpha-1 TLR9 agonist; promotes Treg differentiation SLE, RA, psori
This comparison does not assign a generated winner or score.
- Before choosing a peptide protocol, understanding how thymosin alpha-1 compares to other immune-modulating compounds clarifies which mechanism matches your specific autoimmune profile.
- Thymosin Alpha-1
- TLR9 agonist; promotes Treg differentiation
- SLE, RA, psoriatic arthritis, Crohn's disease
- 1.6mg SubQ 2×/week
- Moderate-high (34–47% increase in CD4+CD25+FoxP3+ cells)
- Most evidence-based for systemic autoimmune conditions; narrow therapeutic window requires precise dosing
- LL-37 (Cathelicidin)
- Antimicrobial peptide; modulates innate immunity
- Skin-based autoimmune (psoriasis, dermatomyositis)
- Topical or 200mcg SubQ daily
- Low (indirect effect)
- Strong for localized inflammation; limited systemic autoimmune efficacy
- Thymosin Beta-4
- Actin sequestration; tissue repair signaling
- Post-inflammatory tissue damage, not active disease
- 5–10mg SubQ 2×/week
- Minimal
- Regenerative, not immunomodulatory. Inappropriate for active autoimmune flares
- BPC-157
- Angiogenic; promotes mucosal healing
- Inflammatory bowel disease (Crohn's, UC)
- 250–500mcg SubQ daily
- Excellent for gut barrier repair; does not address systemic immune dysregulation
- Selank
- Anxiolytic; modulates IL-6 and TNF-alpha
- Stress-induced autoimmune exacerbation
- 300mcg intranasal 2×/day
- None
- Adjunct only. Reduces stress-triggered flares but lacks direct Treg activity
- Thymosin alpha-1 stands apart in this comparison because it targets the upstream immune decision-making process. The dendritic cell maturation that determines whether a T-cell response becomes regulatory or inflammatory. LL-37 and BPC-157 work downstream (tissue repair after inflammation has occurred), while Selank addresses a contributing factor (stress-mediated cytokine release) rather than the core autoimmune mechanism. For patients with systemic autoimmune conditions like lupus or rheumatoid arthritis, Tα1's ability to expand Treg populations by 34–47% (as measured by flow cytometry for CD4+CD25+FoxP3+ markers) makes it the most mechanistically appropriate peptide choice.